Is Biogen's Stock Too Risky to Invest in?
Healthcare company Biogen (NASDAQ: BIIB) has been a volatile one to invest in over the years, to put it mildly. In 2021, its stock hit a high of well over $400. But it also crashed to a low of barely $187 earlier this year. Sharp movements in the share price have been par for the course for Biogen because news about its Alzheimer's treatments has at different times created bullishness and bearishness.
Have things stabilized for Biogen, and is it a good buy right now, or is there still too much risk involved with the company?
Despite what can sometimes appear to be momentary volatility for the stock, shares of Biogen have been trending lower in recent years as the drugmaker's revenue has come under pressure due to the loss of patent exclusivity for its top-selling drug, Tecfidera.
Source Fool.com
